Table 4.
Generalized estimating equation models of risk factors for infectious fungal disease after overall CARV and those limited to the lower respiratory tract
| Factors | GEE IFD (n = 597) | GEE IFD in recipients with CARV LRTD (n = 203) | ||
|---|---|---|---|---|
| OR (95% CI) | Pr(>|W|) | OR (95% CI) | Pr(>|W|) | |
| Intercept | 0.00392 (0.000896‐0.0172) | <0.0001 | 0.00755 (0.000879‐0.0648) | <0.0001 |
| ATG as a part of conditioning | 2.34076 (1.046525‐5.2356) | 0.038 | 3.09494 (1.327891‐7.2134) | 0.009 |
| CARV LRTD | 10.63917 (3.668696‐30.8534) | <0.0001 | nt | nt |
| Allo‐HSCT ≤ 1 y corticosteroids |
5.34718 (1.311639‐21.7989) 2.62746 (1.098765‐6.2830) |
0.014 0.030 |
5.34718 (1.311639‐21.7989) nt |
0.019 nt |
| CARV co‐infection | 0.27566 (0.058127‐1.3073) | 0.105 | 0.27389 (0.055030‐1.3632) | 0.114 |
| Patient CMV status | 2.88806 (0.847759‐9.8387) | 0.090 | 2.31278 (0.644803‐8.2955) | 0.198 |
| Active GvHD at the time RVI | nt | 2.97987 (1.016354‐8.7367) | 0.047 | |
| Estimated scale parameter | 1.21 | 1.15 | ||
| QIC | 178.21 | 134.83 | ||
Abbreviations: Allo‐HSCT, allogeneic hematopoietic stem cell transplantation; ATG, antithymocytic globulin; CARV LRTD, community‐acquired respiratory virus lower respiratory tract disease; CI, confidence interval; GEE, Generalized estimating equation models; GvHD, graft‐versus‐host disease; IFD, infectious fungal disease; nt, not tested; OR, odds ratio; Pr(>|W|), P value of the Wald test; QIC, quasi‐likelihood under the independence model criterion.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.